Prognostic Importance of HALP (Hemoglobin, Albumin, Lymphocyte and Platelet) Score in Ovarian Cancer Patients

Abstract

Objectives: The HALP score, which is the combination of hemoglobin, albumin, lymphocyte, and platelets has been confirmed as an important risk biomarker in several cancers. The aim of this study was to investigate prognostic value of the HALP score in patients with ovarian cancer. Methods: In this study we retrospectively enrolled 185 patients from single center. The relationship between post-op- erative survival outcomes and pre-operative HALP level was assessed using Kaplan-Meier and Cox regression analyses. As a result, the cutoff value of HALP was 27 and patients were then divided into HALP ≤27group and HALP >28 group. Results: A total of 185 women were included in the analysis. 89,7% patients had high grade and %86 patients were advanced stage (62 % were stage III and 24 % were stage IV) serous ovarian cancer. The median survival in the entire population was 54 months (95% CI, 37.57-70.43). Statistical differences were found for HALP score values with stages, platinum resistance status and latest status. In platinum-resistant and platinum-sensitive disease, the area under the curve (AUC) of the receiver operating characteristic (ROC) curve was 0.618 (95% CI, 0.530-0.707), (p=0.008). In patients with high HALP scores, the median progression-free survival was 45 months (95% CI, 0,0-105,32) and in patients with low HALP scores, the median progression-free survival was 15 (95% CI, 13.27-16.72) months and the difference be - tween them was statistically significant (p<0.001). Conclusion: Our study showed that a lower HALP was associated with higher stage and platinum resistance and this score was also an independent factor for poorer oncological outcomes.